Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 12/2015

01-12-2015 | Research Article

Shikonin inhibits invasiveness of osteosarcoma through MMP13 suppression

Authors: Biyong Deng, Bing Qiu

Published in: Tumor Biology | Issue 12/2015

Login to get access

Abstract

Osteosarcoma (OS) is the most common primary malignant bone tumor, notorious for its metastasis. We have recently shown that shikonin, an effective constituent extracted from Chinese medicinal herb, induces necroptosis in OS cells. Nevertheless, the effects of low-dose shikonin on the invasiveness of OS cells are unknown. Here, we showed that shikonin dose-dependently decreased OS cell invasiveness in both scratch wound healing assay and transwell cell migration assay. Moreover, the direct target of shikonin on cell invasiveness was found to be matrix metalloproteinase (MMP)-13. Further, the inhibitory effects of shikonin on cell invasiveness were completely abolished in MMP13-overexpressing OS cells. Together, these data suggest that shikonin may suppress OS invasiveness through MMP13 suppression. Thus, our data highlight a previous unappreciated role for shikonin in suppressing OS cell metastasis.
Literature
1.
Tsuchiya H, Tomita K, Mori Y, Asada N, Morinaga T, Kitano S, et al. Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma. Anticancer Res. 1998;18:657–66.PubMed
2.
Yang J, Zhang W. New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol. 2013;25:398–406.CrossRefPubMed
3.
Li G, Fu D, Liang W, Fan L, Chen K, Shan L, et al. Cyc1 silencing sensitizes osteosarcoma cells to trail-induced apoptosis. Cell Physiol Biochem. 2014;34:2070–80.CrossRefPubMed
4.
Liu Y, He J, Chen X, Li J, Shen M, Yu W, et al. The proapoptotic effect of formononetin in human osteosarcoma cells: involvement of inactivation of erk and akt pathways. Cell Physiol Biochem. 2014;34:637–45.CrossRefPubMed
5.
Wang Q, Cai J, Wang J, Xiong C, Zhao J. Mir-143 inhibits EGFR-signaling-dependent osteosarcoma invasion. Tumour Biol. 2014;35:12743–8.CrossRefPubMed
6.
Xiao Q, Zhang X, Wu Y, Yang Y. Inhibition of macrophage polarization prohibits growth of human osteosarcoma. Tumour Biol. 2014;35:7611–6.CrossRefPubMed
7.
Luo XJ, Tang DG, Gao TL, Zhang YL, Wang M, Quan ZX, et al. Microrna-212 inhibits osteosarcoma cells proliferation and invasion by down-regulation of sox4. Cell Physiol Biochem. 2014;34:2180–8.CrossRefPubMed
8.
Li F, Li S, Cheng T. Tgf-beta1 promotes osteosarcoma cell migration and invasion through the mir-143-versican pathway. Cell Physiol Biochem. 2014;34:2169–79.CrossRefPubMed
9.
He Y, Meng C, Shao Z, Wang H, Yang S. Mir-23a functions as a tumor suppressor in osteosarcoma. Cell Physiol Biochem. 2014;34:1485–96.CrossRefPubMed
10.
Chen J, Fu H, Wang Z, Yin F, Li J, Hua Y, et al. A new synthetic ursolic acid derivative iua with anti-tumor efficacy against osteosarcoma cells via inhibition of JNK signaling pathway. Cell Physiol Biochem. 2014;34:724–33.CrossRefPubMed
11.
Xu H, Liu X, Zhao J. Down-regulation of mir-3928 promoted osteosarcoma growth. Cell Physiol Biochem. 2014;33:1547–56.CrossRefPubMed
12.
Xu G, Wang J, Jia Y, Shen F, Han W, Kang Y. Mir-142-3p functions as a potential tumor suppressor in human osteosarcoma by targeting hmga1. Cell Physiol Biochem. 2014;33:1329–39.CrossRefPubMed
13.
Pan W, Wang H, Jianwei R, Ye Z. Microrna-27a promotes proliferation, migration and invasion by targeting map2k4 in human osteosarcoma cells. Cell Physiol Biochem. 2014;33:402–12.CrossRefPubMed
14.
Chen X, Luther G, Zhang W, Nan G, Wagner ER, Liao Z, et al. The e-f hand calcium-binding protein s100a4 regulates the proliferation, survival and differentiation potential of human osteosarcoma cells. Cell Physiol Biochem. 2013;32:1083–96.CrossRefPubMed
15.
Chang YW, Zhao YF, Cao YL, Gu XF, Li ZQ, Wang SQ, et al. Liver x receptor alpha inhibits osteosarcoma cell proliferation through up-regulation of foxo1. Cell Physiol Biochem. 2013;32:180–6.CrossRefPubMed
16.
Demuth T, Berens ME. Molecular mechanisms of glioma cell migration and invasion. J Neurooncol. 2004;70:217–28.CrossRefPubMed
17.
Shang HS, Chang JB, Lin JH, Lin JP, Hsu SC, Liu CM, et al. Deguelin inhibits the migration and invasion of u-2 os human osteosarcoma cells via the inhibition of matrix metalloproteinase-2/-9 in vitro. Molecules. 2014;19:16588–608.CrossRefPubMed
18.
Chueh FS, Chen YY, Huang AC, Ho HC, Liao CL, Yang JS, et al. Bufalin-inhibited migration and invasion in human osteosarcoma u-2 os cells is carried out by suppression of the matrix metalloproteinase-2, ERK, and JNK signaling pathways. Environ Toxicol. 2014;29:21–9.CrossRefPubMed
19.
Yang GF, Li XH, Zhao Z, Wang WB. Arsenic trioxide up-regulates fas expression in human osteosarcoma cells. Chin Med J (Engl). 2010;123:1768–73.
20.
Zhou X, Yuan B, Yuan W, Wang C, Gao R, Wang J. The expression and clinical significance of high mobility group nucleosome binding domain 5 in human osteosarcoma. Tumour Biol. 2014;35:6539–47.CrossRefPubMed
21.
Zhai M, Cong L, Han Y, Tu G. Cip2a is overexpressed in osteosarcoma and regulates cell proliferation and invasion. Tumour Biol. 2014;35:1123–8.CrossRefPubMed
22.
Meng Q, Zhao J, Liu H, Zhou G, Zhang W, Xu X, et al. Hmgb1 promotes cellular proliferation and invasion, suppresses cellular apoptosis in osteosarcoma. Tumour Biol. 2014;35:12265–74.CrossRefPubMed
23.
Li H, Zhang K, Liu LH, Ouyang Y, Bu J, Guo HB, et al. A systematic review of matrix metalloproteinase 9 as a biomarker of survival in patients with osteosarcoma. Tumour Biol. 2014;35:5487–91.CrossRefPubMed
24.
Jianwei Z, Fan L, Xiancheng L, Enzhong B, Shuai L, Can L. Microrna 181a improves proliferation and invasion, suppresses apoptosis of osteosarcoma cell. Tumour Biol. 2013;34:3331–7.CrossRefPubMed
25.
Jianwei Z, Enzhong B, Fan L, Jian L, Ning A. Effects of kruppel-like factor 6 on osteosarcoma cell biological behavior. Tumour Biol. 2013;34:1097–105.CrossRefPubMed
26.
Futamura N, Nishida Y, Urakawa H, Kozawa E, Ikuta K, Hamada S, et al. Emmprin co-expressed with matrix metalloproteinases predicts poor prognosis in patients with osteosarcoma. Tumour Biol. 2014;35:5159–65.CrossRefPubMed
27.
Ryu B, Li Y, Qian ZJ, Kim MM, Kim SK. Differentiation of human osteosarcoma cells by isolated phlorotannins is subtly linked to Cox-2, iNOS, MMPS, and MAPK signaling: implication for chronic articular disease. Chem Biol Interact. 2009;179:192–201.CrossRefPubMed
28.
Zhou Y, Hu Z, Li N, Jiang R. Interleukin-32 stimulates osteosarcoma cell invasion and motility via AKT pathway-mediated MMP-13 expression. Int J Mol Med. 2015;35:1729–33.PubMed
29.
Osaki M, Takeshita F, Sugimoto Y, Kosaka N, Yamamoto Y, Yoshioka Y, et al. MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression. Mol Ther. 2011;19:1123–30.CrossRefPubMedPubMedCentral
30.
Enomoto M, Hayakawa S, Itsukushima S, Ren DY, Matsuo M, Tamada K, et al. Autonomous regulation of osteosarcoma cell invasiveness by wnt5a/ror2 signaling. Oncogene. 2009;28:3197–208.CrossRefPubMed
31.
Ma O, Cai WW, Zender L, Dayaram T, Shen J, Herron AJ, et al. Mmp13, birc2 (ciap1), and birc3 (ciap2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. Cancer Res. 2009;69:2559–67.CrossRefPubMedPubMedCentral
32.
Andujar I, Rios JL, Giner RM, Recio MC. Pharmacological properties of shikonin—a review of literature since 2002. Planta Med. 2013;79:1685–97.CrossRefPubMed
33.
Andujar I, Recio MC, Giner RM, Rios JL. Traditional Chinese medicine remedy to jury: the pharmacological basis for the use of shikonin as an anticancer therapy. Curr Med Chem. 2013;20:2892–8.CrossRefPubMed
34.
Wang R, Yin R, Zhou W, Xu D, Li S. Shikonin and its derivatives: a patent review. Expert Opin Ther Pat. 2012;22:977–97.CrossRefPubMed
35.
Fu Z, Deng B, Liao Y, Shan L, Yin F, Wang Z, et al. The anti-tumor effect of shikonin on osteosarcoma by inducing rip1 and rip3 dependent necroptosis. BMC Cancer. 2013;13:580.CrossRefPubMedPubMedCentral
36.
Ponten J, Saksela E. Two established in vitro cell lines from human mesenchymal tumours. Int J Cancer. 1967;2:434–47.CrossRefPubMed
37.
Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007;2:329–33.CrossRefPubMed
38.
Inoue A, Takahashi H, Harada H, Kohno S, Ohue S, Kobayashi K, et al. Cancer stem-like cells of glioblastoma characteristically express mmp-13 and display highly invasive activity. Int J Oncol. 2010;37:1121–31.PubMed
Metadata
Title
Shikonin inhibits invasiveness of osteosarcoma through MMP13 suppression
Authors
Biyong Deng
Bing Qiu
Publication date
01-12-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3662-1

Other articles of this Issue 12/2015

Tumor Biology 12/2015 Go to the issue

Research Article

miR-9 promotes cell proliferation and inhibits apoptosis by targeting LASS2 in bladder cancer

Research Article

Resveratrol induces AMPK-dependent MDR1 inhibition in colorectal cancer HCT116/L-OHP cells by preventing activation of NF-κB signaling and suppressing cAMP-responsive element transcriptional activity

Research Article

Growth of glioblastoma is inhibited by miR-133-mediated EGFR suppression

Editorial

The association between methylenetetrahydrofolate reductase gene C677T polymorphisms and breast cancer risk in Chinese population

Research Article

Interaction analysis of IL-12A and IL-12B polymorphisms with the risk of colorectal cancer

Review

Developing strategies to predict photodynamic therapy outcome: the role of melanoma microenvironment
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits